-
Use of Low-Dose Colchicine Safe for
Prevention of Coronary artery Disease, new Study Reveals
19 Apr 2024 18:16 GMT
… use of this medication.
The study results … FDA has recently granted approval for the use of low-dose colchicine … reports, drug registries, and placebo-controlled trials. This analysis … dose colchicine and statin therapy, a commonly prescribed treatment for …
-
Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool
09 Apr 2024 13:00 GMT
… insured patients
Multi-State Medicaid Pharmaceutical Purchasing Group added ELYXYB® … S. Food and Drug Administration (the “FDA”) for the relief … of the anti-gout medicine colchicine indicated for the … the treatment of fibromyalgia, for which Phase 1 trials were …
-
Discovery of potent tubulin polymerization inhibitor that targets tubulin colchicine-binding site
04 Apr 2024 18:49 GMT
-
FDA Approved Drug Products Approval List March 2024
30 Mar 2024 10:39 GMT
… 214369 ORIG-1 RIFAXIMIN NORWICH PHARMACEUTICALS INC Tentative Approval 03 … 761044 SUPPL-13 USTEKINUMAB JANSSEN BIOTECH Approval 03/ … SUPPL-15 PRALSETINIB BLUEPRINT MEDICINES Labeling Approval 03… #215762 ORIG-1 COLCHICINE ANNORA PHARMA Tentative …
-
SGLT2 Inhibitors Reduce Risk of New Gout Diagnoses in T2D Relative to Sulfonylurea
18 Apr 2024 16:44 GMT
… population database and using target trial emulation framework. The database used … gout-specific medication, such as allopurinol, febuxostat, probenecid, or colchicine, unlike their … [SGLT2 inhibitors] in these target trial emulations may guide selection of …
-
Low-dose colchicine may help prevent CV events in patients with type 2 diabetes and MI: COLCOT trial
21 Mar 2024 17:44 GMT
… prespecified analysis of the COLCOT trial, colchicine (0.5 mg daily … COLchicine Cardiovascular Outcomes Trial (COLCOT).
COLCOT was a double-blinded, randomized trial of colchicine … Infarction in the COLchicine Cardiovascular Outcomes Trial (COLCOT). Diabetes …
-
Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba® Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed
20 Mar 2024 15:00 GMT
… of the anti-gout medicine colchicine indicated for the prophylaxis … S. Food and Drug Administration (the “FDA”) for the … the treatment of fibromyalgia, for which Phase 1 trials … FDA is planned. ZTlido® is a registered trademark owned by Scilex Pharmaceuticals …
-
Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid…
20 Mar 2024 13:00 GMT
… wholly owned subsidiary, Scilex Pharmaceuticals Inc. (“Scilex Pharma”, … its FDA-approved liquid colchicine product, Gloperba®, a preventive treatment … the anti-gout medicine colchicine indicated for the … clinical and investigator-initiated trials of SP-102 ( …
-
Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura …
18 Mar 2024 13:00 GMT
… NDS”) to Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, … of the anti-gout medicine colchicine indicated for the prophylaxis … completed a Phase 2 trial in low back pain. … the treatment of fibromyalgia, for which Phase 1 trials were …
-
NSAIDs Decreased the Odds of Adverse Cardiovascular Events in Gout
18 Apr 2024 00:27 GMT
… of nonsteroidal anti-inflammatory drugs (NSAIDs) was not … with anti-inflammatory treatments, including NSAIDs, low-dose colchicine, and… the Department of Clinical Medicine at Aarhus University. “ … non-steroidal anti-inflammatory drugs for gout: a Danish …